Welcome to our dedicated page for Dolby Laboratories SEC filings (Ticker: DLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dolby Laboratories filings document the regulatory disclosures of a technology licensing and cinema-products company whose Class A common stock trades on the New York Stock Exchange under DLB. Recent Form 8-K reports furnish quarterly and annual financial results, dividend declarations for Class A and Class B common stock, and related exhibits.
The company’s proxy and governance filings cover director elections, advisory executive-compensation votes, auditor ratification and executive incentive compensation arrangements. The filings also describe Dolby’s dual-class voting structure, with Class A and Class B common stock voting together on most stockholder matters except where law requires otherwise.
Dolby Laboratories, Inc. SVP and Chief Marketing Officer Todd Pendleton sold Class A Common Stock in an open-market transaction. On May 22, 2026, he sold 11,876 shares at a weighted average price of $54.5518 per share, in multiple trades priced between $54.315 and $55.08.
Following the sale, Pendleton holds 41,480 shares of Class A common stock directly. According to the footnotes, this post-transaction amount includes shares underlying restricted stock units that remain subject to forfeiture until they vest.
DLB submitted a Form 144 notice listing proposed sales of Common Stock that are restricted or performance-based. The filing lists multiple lots with sale dates of 12/15/2025 and 12/16/2025, including examples of 2,109 and 1,928 shares.
Dolby Laboratories SVP Shriram Revankar reported two Class A Common Stock transactions. On May 15, 2026, he sold 3,000 shares in an open-market transaction at $54.90 per share, executed under a Rule 10b5-1 trading plan adopted on August 22, 2025.
On May 18, 2026, 4,329 shares were withheld by Dolby to cover tax obligations from restricted stock unit vesting, a disposition exempt under Rule 16b-3 rather than a market sale. Following these transactions, he directly holds 76,274 shares, including 46,938 shares underlying restricted stock units that remain subject to vesting and 385 shares acquired through the Employee Stock Purchase Plan.
DLB Form 144 reports transactions in Common stock by a reporting holder. The filing shows a sale of 3,000 shares on 02/17/2026 with a reported amount of $198,420. The filing also lists 3,000 restricted shares under a "Securities To Be Sold" entry dated 05/16/2024.
Dolby Laboratories SVP & Chief Financial Officer Robert J. Park reported open-market sales of a total of 4,895 shares of Class A common stock on May 12, 2026. The trades included 391 shares at $57.35 and 4,504 shares at $56.6165, within a price range of $56.335 to $57.13. After these transactions, his holdings include 48,874 shares underlying restricted stock units that remain subject to forfeiture until they vest.
Dolby Laboratories, Inc. Schedule 13G/A Amendment No. 5 reports beneficial ownership stakes held by Morgan Stanley reporting units and Atlanta Capital Management Company, LLC. The filing lists 5,020,777 shares (8.2%) attributed to Morgan Stanley reporting units and 3,925,085 shares (6.4%) attributed to Atlanta Capital Management. The cover shows Class A Common Stock (CUSIP 25659T107) and includes signed joint filing and Item 7 exhibits. Signatures are dated 05/11/2026.
Dolby Laboratories SVP, Entertainment John D. Couling reported multiple stock transactions in Dolby Laboratories, Inc. Class A Common Stock. On May 4–5, 2026, he sold a total of 12,354 shares in open-market transactions at weighted average prices around $57–$58 per share.
On the same date, he also exercised employee stock options covering 7,666 shares at an exercise price of $45.50 per share. A footnote states that shares held following these transactions include 55,114 shares underlying restricted stock units that remain subject to forfeiture until they vest.
The sales were executed in multiple trades within disclosed price ranges and were carried out under a Rule 10b5-1 trading plan adopted on February 3, 2026, indicating they were pre-scheduled rather than discretionary market-timing decisions.
Dorchester Minerals, L.P. (DLB) filing a Form 144 reports a proposed sale of 7,666 shares resulting from a stock option exercise dated 05/05/2026, and discloses prior sales of 4,688 shares on 05/04/2026 for $274,083.92. The filing identifies the broker as Morgan Stanley Smith Barney LLC.
Morgan Stanley Smith Barney LLC filed a Form 144 disclosing an intended sale of 4,688 shares of common stock of DLB. The filing lists separate lots: 2,661 restricted shares, 280 restricted shares, and 1,747 performance shares. The filing notes NYSE and a filing date of 05/04/2026.